Business
Centene Corporation — Know the Business
Centene is a regulated, capital-light spread business on government healthcare dollars, not an insurance float business. FY2025 wiped $7.6B of operating income on a 350+ bp move in the cost-of-revenue ratio — the simultaneous arrival of Medicaid acuity, Marketplace morbidity, and IRA Part D restructuring. The market, at ~0.15x sales and ~1.5x book at $58.81, is pricing the breakage as if it is largely permanent; the bull-bear debate is whether the scale that produced the air pocket (12.5M Medicaid lives at FY25-end, 5.5M Commercial, 8.1M PDP) is the same scale that re-prices the 2026–27 books back to a 3–4% pretax margin.
FY2025 Revenue ($B)
FY2025 Net Loss ($B)
Market Cap ($B, May 2026)
Share Price ($, May 2026)
Book Value / Share ($, FY25-end)
Price / Book (x)
Forward P/E on FY26 guide (x)
Price / Sales (x)
1. How This Business Actually Works
The economic engine is a one-year spread. Centene collects a fixed per-member-per-month (PMPM) premium — set by a state Medicaid agency, CMS, or an ACA Marketplace filing — and pays everything a member needs medically. Premium is locked in 6–12 months ahead. Medical cost is not. The slice that survives — premium minus medical cost minus admin minus regulatory fees — is the entire profit pool. In a normal year that slice is 2–4% of premium pretax. In a bad year, it is negative.
A 200 bp move in HBR — close to what happened in FY25 — is roughly $1.7B of pretax profit per 100 bp at FY25 scale. That single ratio explains almost every year of this company's history. The float (~48 days in claims payable) is too short for investment income to matter.
Three structural facts shape the engine. First, capital intensity is tiny — capex sits under 0.5% of revenue — so the business does not need to reinvest to grow. Second, statutory capital sits trapped inside regulated insurance subsidiaries, so cash at the parent is always less than headline cash; Q1 FY26 ended with $437M of corporate-use cash on a $20B+ corporate balance sheet. Third, scale economies are real but capped — SG&A leverage gives a 100–200 bp moat versus subscale plans (CNC at 7.6% in Q1 FY26 vs. industry tail nearer 10%), but no plan, however large, gets to set the price. The customer is the U.S. government, the price-setter is an actuary at a state Medicaid office or CMS, and the only operating lever inside the year is medical cost management.
Look at FY2023 vs. FY2024 vs. FY2025. Operating income tripled from $1.3B (2022) to $3.2B (2024) on cost-ratio compression of ~320 bp. Then it collapsed by $10.8B on a 350+ bp move the other way. Revenue grew through the entire arc. The cost-of-revenue ratio did the talking.
2. The Playing Field
Centene is the government-programs scale specialist of the six listed MCOs. It is fourth by revenue and last by market cap — the gap is the FY25 loss plus a regulatory-exposure discount. Among diversified peers (UNH, ELV, CI) the read-through is partial; the cleanest comp is Molina, which runs the same Medicaid + Marketplace + low-income Medicare mix at one-fourth the size.
The peer table (FY25 close) reveals four things. One, UNH's P/Sales of 0.67x is double the next peer — that is the Optum services premium, not insurance economics. Strip Optum out and UNH's pure-insurance multiple compresses toward ELV's 0.39x. Two, the pure managed-care multiple cluster sits at 0.20–0.40x P/Sales; CNC at 0.10x at the FY25 close was the cheapest by a wide margin (it has since rerated to ~0.15x at $58.81), the market pricing in either permanent margin impairment or an event-driven binary outcome. Three, ROE differences (UNH 12.5%, ELV 13.3%, CI 15.1%, HUM 7.0%, MOH 11.0%) are smaller than they look because every plan runs a thin equity base — the spread between best and worst-in-class on operating margin is only 250 bp. Four, Molina is the cleanest read-through to CNC; it ran a 1.72% operating margin in FY25 — also a tough year — but stayed profitable while CNC took a $10B-plus reset. That gap is the case study in execution risk inside the same end-market structure.
3. Is This Business Cyclical?
Yes, but not in the way most cyclicals are. There is no consumer demand cycle, no inventory build, no order book. The cycle is a pricing-cost mismatch cycle: rates are negotiated annually and set 6–12 months before they take effect; medical cost can accelerate intra-year on utilization, drug pricing, or risk-pool composition. When cost emerges faster than the actuary forecast, the spread compresses immediately — there is no working-capital buffer because medical claims pay through inside 48 days.
The 2023–24 dip looks like operational breakout. It was actually under-pricing of a deteriorating risk pool. After three years of pandemic-era continuous Medicaid enrollment, the 2023–24 redetermination unwind pushed the lowest-cost members off the rolls and concentrated remaining acuity. Plans had priced 2024–25 rates against a healthier mix and got caught. The 2025 print is the bill arriving.
Three independent shocks landed in 2025 — each large enough on its own, devastating together: Medicaid acuity (sicker remaining pool after redeterminations; rates trailing cost by 100–150 bp); Marketplace morbidity (enhanced APTC subsidies expired end-2025, Silver-to-Bronze migration concentrated higher-acuity members in CNC's Ambetter Silver book, and the segment ended FY25 at a loss); and IRA Part D restructuring (the $2,000 out-of-pocket cap in 2025 — indexed to $2,100 for 2026 — shifted catastrophic costs onto plans; specialty drug trend ran historically high in non-low-income members).
This is also why one-year results mislead. The right way to read managed care is 18 months ahead of the income statement. What CNC prices in summer 2025 shows up in 2H 2026 results; what it bids in May 2026 for 2027 MA plans shows up in 4Q 2027. The Q1 FY26 print (87.3% consolidated HBR, Medicaid HBR improving 50 bp YoY to 93.1%, EPS raised to greater than $3.40) is the first evidence the rate-and-execution loop is closing.
4. The Metrics That Actually Matter
HBR earns or loses the year. Forget P/E. In a normal year, a plan that runs HBR even 100 bp tighter than priced makes 50% more operating income than a plan that prints in line. Conversely, the FY25 result is one ratio (cost / revenue) moving from 78.8% to 82.3% — 350+ bp. Everything else (revenue mix, member count, geographic footprint) is downstream of that.
5. What Is This Business Worth?
This is a normalized-earnings-power business, not a sum-of-the-parts business. Centene has no listed subsidiaries, no separate investment stakes worth carving out, no holding-company discount to unwind. The four operating segments (Medicaid, Marketplace / Commercial, Medicare, Other) share the same regulatory infrastructure, the same provider contracts, and the same Centelligence claims platform. Magellan was impaired in FY25 and is part of the divestiture/wind-down agenda for portfolio cleanup, not because it hid value. The right valuation lens is earnings power on normalized HBR, with a discount applied for regulatory exposure and the FY25 trust impairment.
The valuation question, in one line. If you believe FY24's $3.18B operating income (~1.95% margin) is the right normalized baseline, the stock trades near 9x normalized earnings — cheap. If you believe FY25 marked a structural step-down (regulatory exposure permanently raises required HBR, government will not fund rates fast enough to clear), then forward earnings power is materially lower and the discount is fair. The fork is whether the 350+ bp FY25 cost-of-revenue ratio jump was cyclical (price-cost mismatch that re-prices in 12–18 months) or structural (a permanently sicker risk pool with permanently lagging rates). Q1 FY26 data — Medicaid HBR improving sequentially for the third straight quarter, Marketplace risk-adj turning toward receivable, MA on path to 2027 break-even — leans cyclical. June 2026 Wakely Marketplace data is the next material datapoint.
A sum-of-parts is not the right lens here. Even Molina, the cleanest segment-comp, prices on consolidated managed-care multiples, not segment-level multiples. There is no listed subsidiary or hidden asset whose carve-out value differs materially from the consolidated valuation.
6. What I'd Tell a Young Analyst
Stop tracking EPS. Track HBR by segment and rate yield versus net medical trend. Those two numbers, taken together, will tell you 6–9 months before the Street whether the next year is up or down. Every other ratio is downstream.
Read the rate calendar, not the press release. The CMS MA advance notice in February, the final rate in April, state Medicaid actuarial rate certifications in summer, ACA Marketplace filings in fall — these documents literally set next year's profit pool. Plans win and lose 18 months before earnings catch up.
Days in claims payable is the single best early-warning indicator for reserve adequacy. A sudden drop in DCP while HBR is rising is a sign that claims paid are catching up faster than expected — a reserve risk and a signal of trend acceleration. Centene's 48 days in Q1 FY26, up 2 days sequentially, is healthy. Watch it.
What the market may be missing on Centene specifically. The bear thesis assumes OBBBA Medicaid work requirements, APTC sunset, and IRA Part D restructuring permanently impair the government-programs profit pool. The bull thesis is that these are price-cost reset events — uncomfortable, large, but they have happened before (Medicaid pharmacy carve-outs 2008–10, ACA risk-corridor collapse 2016, COVID utilization swings 2020–22) and the survivors always come out repriced. Centene survived all three. What is different this time is that the company took the loss without breaking — corporate cash rose, $1B of senior notes were retired, debt-to-cap fell from 46.5% to 43.2% in one quarter, and FY26 EPS guidance was raised mid-cycle. The action under the surface looks like a managed reset, not a structural break.
Three things that would change the thesis. (1) A second consecutive year of consolidated HBR at or above 91% with no compensating rate cycle — that would say the cost structure has reset higher. (2) Loss of a top-3 state Medicaid contract on renewal — would signal customer trust impairment, not market-level shock. (3) A Star-ratings drop below 3.0 on a material MA contract — would compress MA economics permanently and reduce optionality on the 2027 break-even path. None of these has happened. The first signal you would see is in October 2026 Stars and the late-2026 state Medicaid renewals.
Centene is the government-programs scale specialist of U.S. managed care, priced at ~0.15x sales (~0.10x at FY25 close) because the market has not yet decided whether FY25 was a single bad year or a structural reset. The data trail — Q1 FY26 Medicaid HBR -50 bp YoY to 93.1%, debt down, parent cash up, EPS guide raised — favors cyclical. Watch June 2026 Wakely (Marketplace risk-adj), October 2026 CMS Stars, and 2027 state Medicaid rate certifications. Those three datapoints will decide whether the normalized-earnings argument holds.